Humacyte Inc. HUMA stock plunged Thursday despite reporting positive interim Phase 3 data for its acellular tissue-engineered ...

Clinical trial findings showed Avance was noninferior to a collagen nerve cuff for returning sensory function in patients with nerve injuries in the hand. The Food and Drug Administration (FDA) has ...

Humacyte recently reported research showing its acellular tissue engineered vessel (ATEV) used for dialysis access can self-repair after repeated needle cannulation, maintaining structural integrity ...

In a trial, an acellular tissue engineered vessel had superior functional patency for hemodialysis with acceptable safety compared with an arteriovenous fistula in high-risk patients. An acellular ...

DURHAM, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

Pain is something we all dread, especially when it lingers and stops us from doing what we love. For Kanta Devi, 62, this became a harsh reality. In 2020, during her morning jog, she fell and hurt her ...

DURHAM, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at ...

The U.S. Food and Drug Administration has approved Symvess, the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent ...

Background: The transition from a whole-cell to a 5-component acellular pertussis vaccine provided a unique opportunity to compare the effect that each type of vaccine had on the incidence of ...

Risk factors for postoperative complications of a randomized clinical trial: Laparoscopic versus open surgery with D3 lymphadenectomy for stage II/III colon cancer (JCOG0404). Repeated ...